CZ247092A3 - Cyklopentenové deriváty - Google Patents
Cyklopentenové deriváty Download PDFInfo
- Publication number
- CZ247092A3 CZ247092A3 CS922470A CS247092A CZ247092A3 CZ 247092 A3 CZ247092 A3 CZ 247092A3 CS 922470 A CS922470 A CS 922470A CS 247092 A CS247092 A CS 247092A CZ 247092 A3 CZ247092 A3 CZ 247092A3
- Authority
- CZ
- Czechia
- Prior art keywords
- methanol
- cyclopentene
- amino
- formula
- compounds
- Prior art date
Links
- 125000002433 cyclopentenyl group Chemical class C1(=CCCC1)* 0.000 title claims 4
- 150000003839 salts Chemical class 0.000 claims description 11
- NTBIYBAYFBNTCD-KBPBESRZSA-N dibenzoyl (2s,3s)-2,3-dihydroxybutanedioate Chemical compound O=C([C@@H](O)[C@H](O)C(=O)OC(=O)C=1C=CC=CC=1)OC(=O)C1=CC=CC=C1 NTBIYBAYFBNTCD-KBPBESRZSA-N 0.000 claims description 3
- UXKZFJDNFBNQHE-RITPCOANSA-N [(1s,4r)-4-aminocyclopent-2-en-1-yl]methanol Chemical compound N[C@@H]1C[C@H](CO)C=C1 UXKZFJDNFBNQHE-RITPCOANSA-N 0.000 claims description 2
- UXKZFJDNFBNQHE-NTSWFWBYSA-N [(1r,4s)-4-aminocyclopent-2-en-1-yl]methanol Chemical compound N[C@H]1C[C@@H](CO)C=C1 UXKZFJDNFBNQHE-NTSWFWBYSA-N 0.000 claims 1
- NTBIYBAYFBNTCD-ZIAGYGMSSA-N dibenzoyl (2r,3r)-2,3-dihydroxybutanedioate Chemical compound O=C([C@H](O)[C@@H](O)C(=O)OC(=O)C=1C=CC=CC=1)OC(=O)C1=CC=CC=C1 NTBIYBAYFBNTCD-ZIAGYGMSSA-N 0.000 claims 1
- -1 N-cyclopropyl-N-methylamino Chemical group 0.000 abstract description 5
- 239000002777 nucleoside Substances 0.000 abstract description 4
- 125000003835 nucleoside group Chemical group 0.000 abstract description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract 2
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 241000725303 Human immunodeficiency virus Species 0.000 description 9
- 241000700721 Hepatitis B virus Species 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 3
- UXKZFJDNFBNQHE-UHFFFAOYSA-N (4-aminocyclopent-2-en-1-yl)methanol Chemical compound NC1CC(CO)C=C1 UXKZFJDNFBNQHE-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 125000006317 cyclopropyl amino group Chemical group 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- XSSYCIGJYCVRRK-RQJHMYQMSA-N (-)-carbovir Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1C[C@H](CO)C=C1 XSSYCIGJYCVRRK-RQJHMYQMSA-N 0.000 description 1
- OCQAXYHNMWVLRH-QZTJIDSGSA-N (2r,3r)-2,3-dibenzoyl-2,3-dihydroxybutanedioic acid Chemical class O=C([C@@](O)(C(=O)O)[C@](O)(C(O)=O)C(=O)C=1C=CC=CC=1)C1=CC=CC=C1 OCQAXYHNMWVLRH-QZTJIDSGSA-N 0.000 description 1
- WADJLAVWIMPNPC-UHFFFAOYSA-N 2,3-dibenzoyloxy-2,3-dihydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)OC(O)(C(O)=O)C(O)(C(=O)O)OC(=O)C1=CC=CC=C1 WADJLAVWIMPNPC-UHFFFAOYSA-N 0.000 description 1
- DDUFYKNOXPZZIW-UHFFFAOYSA-N 3-azabicyclo[2.2.1]hept-5-en-2-one Chemical compound C1C2C(=O)NC1C=C2 DDUFYKNOXPZZIW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- ZUDYPQRUOYEARG-UHFFFAOYSA-L barium(2+);dihydroxide;octahydrate Chemical compound O.O.O.O.O.O.O.O.[OH-].[OH-].[Ba+2] ZUDYPQRUOYEARG-UHFFFAOYSA-L 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- CWIHMSCCCFHZDA-UHFFFAOYSA-N cyclopentene methyl acetate Chemical compound C(C)(=O)OC.C1=CCCC1 CWIHMSCCCFHZDA-UHFFFAOYSA-N 0.000 description 1
- 150000001941 cyclopentenes Chemical class 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229960001270 d- tartaric acid Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- IRUNKQSGDBYUDC-UHFFFAOYSA-N diethoxymethyl acetate Chemical compound CCOC(OCC)OC(C)=O IRUNKQSGDBYUDC-UHFFFAOYSA-N 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000000652 homosexual effect Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- SWYRZYIXFKDJEK-IBTYICNHSA-N methyl (1s,4r)-4-aminocyclopent-2-ene-1-carboxylate;hydrochloride Chemical compound Cl.COC(=O)[C@H]1C[C@@H](N)C=C1 SWYRZYIXFKDJEK-IBTYICNHSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- VEBLEROFGPOMPB-UHFFFAOYSA-N n-methylcyclopropanamine Chemical compound CNC1CC1 VEBLEROFGPOMPB-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Vynález se zvláště týká enantiomerů 4-amino-2-cyklopenten-1-methanolu a jeho solí, zvláště příslušných dibenzoyl-D-tartrátů.
Dosavadní_£tav_techniky
AIDS (syndrom získané imunitní nedostatečnosti) je choroba potlačující imunitu neboli imunodestruktivní choroba, která předurčuje pacienta k smrtící příležitostné infekci. AIDS je příznačně spojen s progresivním úbytkem
T-buněk, zvláště podskupiny, která nese povrchový buněčný znak OKT .
Virus lidské imunitní nedostatečnosti (HIV) byl reprodukovatelně izolován od pacientů trpících AIDS nebo příznaky, které často předcházejí AIDS. HIV má cytopatický
Λ’· charakter a přednostně infikuje a ničí T-bunky nesoucí bu4 něčný znak OKT a nyní je obecně uznáváno, že HIV je hybnou /
silou, která je příčinou AIDS.
Protože bylo nalezeno, že HIV je hybnou silou zapříčiňující AIDS, byla učiněna řada návrhů chemoterapeutických prostředků působících proti HIV, které mohou být účinné při ošetřování poškozeni, které vyvolává AIDS. Tak například US patent Č. 4 724 232 popisuje 3'-azido-3'-deoxythymidin (pro který bylo schváleno označení zidovudin), jeho deriváty přijatelné z farmaceutického hladiska a jejich použití pří ošetřováni infekci člověka způsobených retroviry.
_ 9 včetně AIDS a souvisejících klinických stavů. Vince a kol. v Antiviral Research 9 (1/2), 120 /1988/ popisuje určité karbocyklická nukleosidová analogy a 'jejich použiti proti HIV. Od druhé mezinárodní konference o výzkumu boje proti virům, konané ve Williamsburgu (VA, USA) ve dnech 10. až 14.dubna 1988,, je znám (-)-9-/cis-4-(hydroxymethyl)-2-cyklopentenyl/guanin, který je také známý pod označením carbovir.
Oiným světověrozšířeným virovým patogenem častého výskytu je virus hepatitidy B (HBV), Nejběžnějši je v asijských zemích a převažuje v subsaharské Africe.
Virus je z hlediska původu spojen s primárním hepatocelulárnim karcinomem.
V USA se průběžně vyskytuje podle odhadu skupina čítající 500 000 až 1 milion nosičů infekce. Chronická aktivní hepatitida se vyvine u více než 25 % nosičů a často dochází k cirrhoze. Odhaduje se, že každoročně v USA umírá 5000 lidí na cirrhozu spojenou s HBV a že patrně 1000 úmrtí pochází od zhoubného náďcrýu jater, souvisejícího s HBV, I když je k dispozici univerzální HBV vakcína, pokračuje potřeba nalézt sloučeniny, které jsou účinné proti HBV, Velké zásobárně trvale infikovaných nosičů, odhadované na 220 milionů lidí na celém světě, není možné pomoci vakcínou a pokračuje vysoké riziko jsterních chorob vyvolaných HBV. Nosiči v populaci slouží jako zdroj infekce pro citlivé jedince a opakovaně vyvolávají choroby, zvláště v endemických oblastech nebo u vysoce rizikových skupin, jako jsou narkomani navyklí na drogu IV a homosexuálové.
Tak se naskýtá vysoká potřeba účinných prostředků proti virům, jek k potlačování chronické infekce, tak ke snížení postupu vývoje hepatocelulárního karcinomu.
Klinické účinky infekcí vyvolaných HSV virem se
- 3 projevují bolestí hlavy, horečkou, projevy zneklidnění, nucením k zvracení, dávením, anorexií a bolestmi břicha. Replikace viru- se obvykle potlačuje imunitní odezvou s průběhem uzdravování trvajícím týdny nebo měsíce u člověka, ale infekce může ve vážnějších případech vést k neodstranitelným chronickým jaternim chorobám, jak bylo uvedeno výše.
Evropský patentový spis č. 349 242 popisuje určité purinové karbocyklické nukleosidy substituované v poloze 6 a jejich použití v léčebné terapii, zvláště k ošetřování infekcí vyvolaných HIV a HSV. Mezi takové nukleosidy náleží sloučeniny (i)-cis-4-/2-amino-6-(cyklopropylamino)-9H-pirin-9-yl/-2-cyklopenten-l-methanol a (-)-cis-4-/2-amino-6-( cy klop ropy lme thy lamino )-9H-pu rin- 9-yXZ-2-cyklopenten-l-methanol, to znamená každá z těchto sloučenin ve formě racemické směsi nebo svých příslušných enantiomerů.
Nyní bylo nalezeno, že jednotlivé izolované enantiomery obou sloučenin uvedených výše a jejich deriváty přijatelné z farmaceutického hlediska mají výhodnou protivínovou aktivitu, zvláště jsou účinné proti infekcím vyvolaným HIV a HBV viry, přičemž tato účinnost je spojena s nízkou cytotoxicitou a/nebo tyto sloučeniny jsou vhodné jako meziprodukty pro výrobu sloučenin, které mají uvedenou aktivitu.
Na základě těchto skutečností nastala potřeba vypracovat nový způsob výroby takových sloučenin, který by vycházel ze sloučenin technicky snadno dostupných, které je možné vyrábět za příznivých ekonomických podmínek. Takovou možnost nabízí tento· vynález.
Podstatu vynálezu tvoří cyklopentenové deriváty vzorce VIIIA a VIII 3
a jejich soli.
Oe zřejmé, že tyto sloučeniny zahrnují (1S ,4R)-4-amino-2-cyklopenten-l-methanol a jeho deriváty v podstatě zbavené (IR, AS) enantiomerů a (lR.4S)-4-aniino-2-cyklopenten-l-methanol a jeho deriváty v podstatě zbyvené (1S.4R) enantiomerů.
Obsah druhého enantiomerů je menší než 10 % hmotnostních, s výhodou menší než 5 % hmotnostních.
Deriváty enantiomerní sloučeniny vzorce VIIIA a VIII3 jsou zvláště soli s opticky aktivními karoocyklickými kyselinami, jako je kyselina dibenzol-D-vinná. Ode tedy například c (13,4R)-4-amino-2-cyklopenten-l-methanol a jeho dibsnzoyl-D-tartrát a (lR,43)-4-amino-2-cyklopenten-l-methanol a jeho dibenzoyl-D-tartrát.
Sloučeniny vzorce VIIIA a VIIIB, které mají vhodnou enantiomerni konfiguraci, se mohou získat zpracovánim odpovídající racemická sloučeniny, to jest (-)-4-amino-2-cyklopenten-l-methanolu, s opticky aktivní karbocyklickou kyselinou (například kyselinou dibenzoyl-D-vinnou) a potom frakční krystalizací výsledných diatereomerních solí.
Při jiném provedení se může použít enzymatického štěpení, jak je například popsáno v 0. Med. CHem. 3(3, 746 / 1987/ a 3. Mec
Chem.28, 1385 /1985/.
Průmysloyá_využitelnost
a.
Sloučeniny vzorce VIIIA a VIII3 nacházejí použití jako výchozí látky pro výrobu enantiomerních sloučenin obecného vzorce IA a IB
ve kterých
R představuje cyklopropylaminoskupinu nebo
N-cyklopropyl-N-methylaminoskupinu a
D představuje hydroxyskupinu nebo esterifikovanou hydroxyskupinu, a jejich fyziologicky přijatelných soli, bučí v (1S,4R) nebo (1R.4S) konfiguraci a jejich fyziologicky přijatelných solí, přičemž sloučeniny a soli jsou vždy ve formě enantiomeru, jenž je v podstatě zbaven příslušného druhého enantiomeru.
Výraz v podstatě zbaven příslušného druhého enantiomeru znamená, že obsah tohoto druhého enantiomeru je menší než 10 % hmotnostních, s výhodou menši než 5 % hmotnostních.
Při výrobě enantiomernich sloučenin obecného vzorce IA a 13 se postupuje tak, že se enantiomerní sloučenina svrchu uvedeného obecného vzorce VIIIA nebo VIIID nebo jejich derivát nechá reagovat se sloučeninou obecného vzorce VII
NHR“
ve kterém představuje prekurzorovou skupinu nebo skupinu
R vymezenou u obecného vzorce IA a 18,
R9 představuje atom vodiku nebo formylovou skupinu.
R' znamená skupinu chránící aminoskupinu, například acylovou skupinu, například alkanoylovou skupinu s 1 až 6 atomy uhlíku, jako je formylová skupina, acetylová skupina nebo isobutyry lová skupina a představuje odštěpitelnou skupinu, například atom halogenu, jako atom chloru, nebo jejím derivátem, za vzniku enantiomerniho meziproduktu obecného vzorce V
A ve kterém
A znamená 2-cyklopenten-l-methanol-4-ylovou skupinu a 3
Z, R a R mají význam uvedený výše, nebo jeho derivátu.
Tato reakce se s výhodou provádí v přítomnosti báze, jako terciárního aminu, například triethylaminu nebo trimethylaminu, v organickém rozpouštědle, jako je dimethoxyethan nebo ethanol.
Enantiomerní meziprodukt obecného vzorce V se dále nechá reagovat s činidlem sloužícím k vytvoření imidazolového kruhu a k účinnému odstraněni skupiny chránící aminoskupinu R3, za vzniku sloučeniny obecného vzorce II •7
A ve kterém
A a Z mají význam uvedený výše.
Tento reakční stupen/může provést například reakcí enantiomerního meziproduktu obecného vzorce V s kyselinou mravenčí nebo jejím reaktivním derivátem 'například triethyl-ortoformiátem nebo dieťnoxymethylacetátem), popřípadě se spolurozpouštědlem, jako je dimethylacetamid nebo dimethylformamid, za zvýšené teploty, s výhodou za teploty od 75 do 90 °C. Tato reakce se obvykle provádí za přídavku silné bezvodé kyseliny, který je větší než 1 ekvivalent, například za přídavku 1,1 ekvivalentu kyseliny ethansulfonové na 1 ekvivalent sloučeniny obecného vzorce V, V tomto případě se používá nižších teplot (například 25 °G).
Konečně získaná sloučenina obecného vzorce II nebo její derivát se v dalším reakčním stupni zpracuje s činidlem sloužícím k převedení prekursorové skupiny Z na požadovanou skupinu R, za vzniku enantiomerní sloučeniny rozsahu uvedeného obecného vzorce IA nebo 13.
Tato reakce se může provádět obvyklým postupem, například zpracováním sloučeniny obecného vzorce II, ve kterém Z představuje.odštěpitelnou skupinu (například atom halogenu, jako atom chloru), s výhodným aminem, to je cyklopropylaminem nebo N-cyklopropyl-N-methylaminem, který se použije v přebytku k zavedeni aminoskupiny R vymezené výše, při výhodném provedeni za teploty zpětného toku nebo za teploty vyšší než 50 °C. Způsob se účelně provádí v přítomnosti organického rozpouštědla, například methanolu nebo ethanolu.
Příklady_grovedení_vvnálezu_
Následující příklady jsou určeny toliko 'pro ilustraci a žádným způsobem nejsou zamýšleny jako omezeni rozsahu vynálezu. Příklady optické otáčivostí jsou označovány s ohledem na čáru 0 sodíku (589 nm) za teploty 20 °C,
Přiklad 1
Způsob výroby dibenzoyl-D-tartátu (lS,4R)-4-amino-?.-cyklopenten-1-metanol'J
14,53 g (0,073 mol) (-)-cis-4-acetamidu
2-cyklopentenmethylacetátu (U3 patent č, 4 258 572) a 46,19 g (0,145 mol) oktahydrátu hydroxidu barnatáho se vaří pod zpětným chladičem ve 300 ml vody pod dusíkovou atmosférou po dobu 18 hodin. Výsledný roztok se neutralizuje oxidem uhličitým. Sraženina se promyje vodou a potom ethanolem. Spojené filtráty se odpaří na sirup (sůl vzniklou z kyseliny octové a (-)-4-amino-2-cyklopenten-l-methanolu) a tento sirup se převede na volný amin tím, že se smíchá s přebytkem pryskyřice Amberlite IRA-400 (OH) ve vodě. Pryskyřice se odfiltruje, promyje vodou a promytý filtrát se odpaří na světle žlutý sirup, který se vysuší odpařením etnanolového podílu. Vzorek tohoto aminu o hmotnosti 2,25 g (20,0 mmol) a 3,52 g (10,0 mmol) kyseliny dibenzoyl-O-vinné (99% obsah, Aldrich) se rozpustí v 35 ml horkého absolutního ethanolu,
K tomuto roztoku se až do bodu zákalu přidává acetonitril udržovaný ve varu pod zpětným chladičem (přibližně 150 ml) a získaný roztok se nechá pomalu ochladit na teplotu místnosti. Vytvoří se bílé jehličky, které se třikrát rekrystaluji ze stejná kombinace rozpouštědel na sloučeninu pojmenovanou v nadpise příkladu, tvořenou bílými destičkami. Získaná látka má hmotnost 1,07 g, co odpovídá 37 % teorie. Teplota tání činí 160 až 152 °C.
/<£/§° +6Qf9 o /oC/^g +155 0 (c = 0,28, methanol).
/</ ,20
003 + 325 π Krystalografie této soli stanovená pomocí rentgenová záření ukazuje na absolutní konfiguraci kationtu, který je fixován známým uspořádáním dianiontu kyseliny dibenzoyl-D-vinná, Tato sůl krystaluje v prostorové skupině 02 s jedním kationtem C-H^NO a polovinou dianiontu 0ΊΟΗ.^0θ jako asymetrická jednotka.
Analýza .pro OgH^^NO. O, 5C-, θΗ^Οθ:
vypočteno nalezeno;
61,53 % C, 61,36 % C, r- >_i ,3 π»
5,21
5,24
4,79 % N,
4,74 %
Přiklad 2
9(-n /j Způsob výroby ditffizoyl-L-taCtrátu (12,43)-4-amino-2-cyklopenten-l-methanolu
Tato sůl se vyrobí a krystaluje jako v příkladě 1 s tím rozdílem, že se použije kyseliny dibenzoyl-L-vinné, Trojnásobnou krystalizací ze směsi ethanolu a aceto nitrilu se dostane 1,00 g sloučeniny pojmenovaná v nadpise, jako bilé destičky. Výtěžek čini 34 % teorie. Teplota tání je 130 až 152 °C, /<£/
-38,2 /<4/ c = 0,24, methanol).
436
-159
-333
Analýza pro ΟθΗ^^Νθ^θ.δΟ^θΗ^^Οθ:
vypočteno: nalezeno:
61,63 % C, 61.59 % C,
5.21 % H, 4,79 ;ó N.
6.21 % H, 4,75 % M.
Příklad 3
Způsob výroby dibenzoyl-O-tartáru (15,42)-4-amin0-2-cyklopenten-l-methanolu
44,0 g (0,400 mol) 2-azabicyklo/’2,2, l/hept-5-en-3-onu (Daluge a Vince, 3, Org. Cíiem, 43, 2311 /1978/ a >J5 pat^e.nt č. 4 258 572) se míchá v 0,5 litru 2-normální kyseliny chlorovodíková v methanolu za teploty 25 C po dobu 1,5 hodiny. Těkavá složky se odpaří a dostane se 71,1 hydrochloridu i)-cis-methyl-4-amino-2-cyklopenten-l-karboxylátu, který tvoří bšlavý prášek. Trituraci vzorku tohoto rr prášku s diethyletherem se dostane bílý prášek, který má teplotu tání 92,5 až 95 °q[(3. Org. Chem. 43, 3271 /1981/ uvádí teplotu tání 82 až 33 °C).
NMR spektrum (/*CH272S0“dg) <f : 8,25 (široký singlet, 3, NH^*), 6,1 a 5,9 (oba m, 2, CH=CH), 3,54 (s), překrývající se 3,75 - 3,5 (m, celkově 4, OCH a CH),
2,55 - 2,45 a 2,05 - 1,85 <oba m, 2, CH^) ppm.
Analýza pro C vypočteno: nalezeno:
p | 5,81 % H, 7,89 % N, | 19,95 % | Cl |
6,34 A H, 7,85 ij N, | 19,89 Sj | Cl |
47,33 %
47,41 /
Hydrochlorid (-)-cis-methy1-4-amino-2-cyklopenten-l-karboxylátu o hmotnosti 17,7 g (0,100 mol) a 0,500 mol diisobutylaluminiumhydridu ve formě 1-molárního roztoku v hexanu se vaří pod zpětným chladičem s 200 ml hexanu po dobu 5 hodin. Výsledný roztok se ochladí a přidá se k němu 10 ml 1-molárního roztoku chloridu amonného a potom 200 ml methanolu. Získaná směs se vaří pod zpětným chladičem po dobu 30 minut a poté se přidá 10 g síranu hořečnatého. Pevné podíly se odfiltruji a promyjí dalším methanolem. Promytý filtrát se odpaří na tmavý olej o hmotnosti 15,5 g.
^H NMR spektrum (/CH-J^SO-d,.,) je identické + J O se spektrem (-)-4-amino-2-cyklopentax-l-methanolu, který byl vyroben jak je popsáno v příkladu 1, Vzorek po chromatografickém přečištění na silikagelu (při eluování směsí ethanolu, chl^oformu a hydroxidu amonného v poměru 10:90:1) se krystaluje s kyselinou dibenzoyl-D-vinnou za vzniku sloučeniny pojmenované v nadpise.
/7
Claims (3)
1. Cyklopentenové deriváty vzorce VIIIA nebo VIII3 (VIIIA) (VIII2) a jejich soli,
2. Cyklopentenový derivát podle nároku 1, (IS, 4R)4-amino-2-cyklopenten-l-methanol a jeho dibenzoyl-D-tartrát s obsahem méně než 10 % odpovídajícího (IR,4S)-enantiomeru.
3. Cyklopentenový derivát podle nároku 1, (1R,4S)4-amino-2-cyklopenten-l-methanol a jeho dibenzoyl-L-tartrát s obsahem méně než 10 % odpovídajícího (1S.4R)-enantiomeru.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB888815265A GB8815265D0 (en) | 1988-06-27 | 1988-06-27 | Therapeutic nucleosides |
US07/455,201 US5034394A (en) | 1988-06-27 | 1989-12-22 | Therapeutic nucleosides |
Publications (2)
Publication Number | Publication Date |
---|---|
CZ247092A3 true CZ247092A3 (cs) | 1998-04-15 |
CZ283786B6 CZ283786B6 (cs) | 1998-06-17 |
Family
ID=10639435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CS922470A CZ283786B6 (cs) | 1988-06-27 | 1990-12-21 | Cyklopentenové deriváty |
Country Status (26)
Country | Link |
---|---|
US (5) | US5034394A (cs) |
EP (1) | EP0349242B1 (cs) |
JP (3) | JP2875814B2 (cs) |
KR (1) | KR0140532B1 (cs) |
AP (1) | AP101A (cs) |
AT (1) | ATE120194T1 (cs) |
AU (1) | AU636108B2 (cs) |
CA (1) | CA1340589C (cs) |
CY (1) | CY2018A (cs) |
CZ (1) | CZ283786B6 (cs) |
DE (1) | DE68921798T2 (cs) |
DK (1) | DK174668B1 (cs) |
ES (1) | ES2069582T3 (cs) |
FI (2) | FI893113A (cs) |
GB (1) | GB8815265D0 (cs) |
GR (1) | GR3015966T3 (cs) |
HK (1) | HK85897A (cs) |
HU (2) | HU206353B (cs) |
IE (1) | IE68038B1 (cs) |
IL (1) | IL90752A (cs) |
LV (1) | LV5781B4 (cs) |
MY (1) | MY104043A (cs) |
NZ (1) | NZ229716A (cs) |
PT (1) | PT90973B (cs) |
UA (1) | UA29382C2 (cs) |
ZA (1) | ZA894837B (cs) |
Families Citing this family (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5175292A (en) * | 1988-01-20 | 1992-12-29 | Regents Of The University Of Minnesota | Intermediates for the preparation of dideoxycarbocyclic nucleosides |
SE505213C2 (sv) * | 1988-01-20 | 1997-07-14 | Univ Minnesota | Dideoxikarbocykliska nukleosidanaloger, farmaceutiska beredningar därav samt mellanprodukter |
GB2243609B (en) * | 1988-01-20 | 1992-03-11 | Univ Minnesota | Dideoxydidehydrocarbocyclic pyrimidines |
US5631370A (en) * | 1988-01-20 | 1997-05-20 | Regents Of The University Of Minnesota | Optically-active isomers of dideoxycarbocyclic nucleosides |
US6903224B2 (en) | 1988-04-11 | 2005-06-07 | Biochem Pharma Inc. | Substituted 1,3-oxathiolanes |
US5270315A (en) * | 1988-04-11 | 1993-12-14 | Biochem Pharma Inc. | 4-(purinyl bases)-substituted-1,3-dioxlanes |
US7119202B1 (en) | 1989-02-08 | 2006-10-10 | Glaxo Wellcome Inc. | Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties |
US6350753B1 (en) | 1988-04-11 | 2002-02-26 | Biochem Pharma Inc. | 2-Substituted-4-substituted-1,3-dioxolanes and use thereof |
GB8815265D0 (en) * | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
CA2001401A1 (en) * | 1988-10-25 | 1990-04-25 | Claude Piantadosi | Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions |
KR910700054A (ko) * | 1988-12-12 | 1991-03-13 | 엠. 팔레스 피터 | B형 간염 비루스 감염의 예방 및 치료를 위한 방법 및 조성물 |
UA45942A (uk) * | 1989-02-08 | 2002-05-15 | Біокем Фарма, Інк. | 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція |
ES2136061T3 (es) * | 1989-06-27 | 1999-11-16 | Wellcome Found | Nucleosidos terapeuticos. |
MY104575A (en) * | 1989-12-22 | 1994-04-30 | The Wellcome Foundation Ltd | Therapeutic nucleosides. |
US5728575A (en) * | 1990-02-01 | 1998-03-17 | Emory University | Method of resolution of 1,3-oxathiolane nucleoside enantiomers |
US5144034A (en) * | 1990-04-06 | 1992-09-01 | Glaxo Inc. | Process for the synthesis of cyclopentene derivatives of purines |
US5126452A (en) * | 1990-04-06 | 1992-06-30 | Glaxo Inc. | Synthesis of purine substituted cyclopentene derivatives |
GB9009861D0 (en) | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
US5470857A (en) * | 1990-09-14 | 1995-11-28 | Marion Merrell Dow Inc. | Carbocyclic nucleoside analogs useful as immunosuppressants |
US5340816A (en) * | 1990-10-18 | 1994-08-23 | E. R. Squibb & Sons, Inc. | Hydroxymethyl(methylenecyclopentyl) purines and pyrimidines |
US5206244A (en) * | 1990-10-18 | 1993-04-27 | E. R. Squibb & Sons, Inc. | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines |
US5587480A (en) * | 1990-11-13 | 1996-12-24 | Biochem Pharma, Inc. | Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties |
US6369066B1 (en) | 1990-11-13 | 2002-04-09 | Biochem Pharma, Inc. | Substituted 1,3-oxathiolanes with antiviral properties |
US6228860B1 (en) | 1990-11-13 | 2001-05-08 | Biochem Pharma Inc. | Substituted 1,3-oxathiolanes with antiviral properties |
US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
IL100502A (en) * | 1991-01-03 | 1995-12-08 | Iaf Biochem Int | PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (- |
GB9110874D0 (en) * | 1991-05-20 | 1991-07-10 | Iaf Biochem Int | Medicaments |
ZA923640B (en) * | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
US5233041A (en) * | 1991-10-07 | 1993-08-03 | Glaxo Group Limited | Synthesis of a 3,4-dihydroxy-1-cyclopentanylpurinone from a 2,3-unsaturated-1-cyclopentanylpurinone |
GB9204015D0 (en) * | 1992-02-25 | 1992-04-08 | Wellcome Found | Therapeutic nucleosides |
GB9217823D0 (en) * | 1992-08-21 | 1992-10-07 | Glaxo Group Ltd | Chemical process |
US5329008A (en) * | 1993-04-07 | 1994-07-12 | Glaxo Inc. | Synthesis of a 3,4-dihydroxy-1-cyclopentanylpurinone |
US5654286A (en) * | 1993-05-12 | 1997-08-05 | Hostetler; Karl Y. | Nucleotides for topical treatment of psoriasis, and methods for using same |
ATE226437T1 (de) * | 1993-06-10 | 2002-11-15 | Univ Wake Forest | (phospho)lipide zum bekämpfen einer hepatitis b- infektion |
ATE151423T1 (de) | 1993-06-21 | 1997-04-15 | Merrell Pharma Inc | Carbocyclische nucleoside mittel nützlich als selektive inhibitoren von proinflammatorischen cytokinen |
US20020120130A1 (en) * | 1993-09-10 | 2002-08-29 | Gilles Gosselin | 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents |
US5587362A (en) * | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
GB9402161D0 (en) * | 1994-02-04 | 1994-03-30 | Wellcome Found | Chloropyrimidine intermediates |
US5994361A (en) * | 1994-06-22 | 1999-11-30 | Biochem Pharma | Substituted purinyl derivatives with immunomodulating activity |
GB9417249D0 (en) * | 1994-08-26 | 1994-10-19 | Wellcome Found | A novel salt |
US5962437A (en) * | 1994-08-29 | 1999-10-05 | Wake Forest University | Lipid analogs for treating viral infections |
US7135584B2 (en) * | 1995-08-07 | 2006-11-14 | Wake Forest University | Lipid analogs for treating viral infections |
US5703058A (en) * | 1995-01-27 | 1997-12-30 | Emory University | Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent |
US6391859B1 (en) | 1995-01-27 | 2002-05-21 | Emory University | [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides |
US5808040A (en) * | 1995-01-30 | 1998-09-15 | Yale University | L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides |
MY115461A (en) * | 1995-03-30 | 2003-06-30 | Wellcome Found | Synergistic combinations of zidovudine, 1592u89 and 3tc |
DE69636734T2 (de) | 1995-06-07 | 2007-10-18 | Emory University | Nucleoside mit anti-hepatitis b virus wirksamkeit |
CA2190202C (en) | 1995-11-17 | 2005-07-26 | Nobuya Katagiri | Cyclopentenecarboxamide derivative, method for preparing the same and bicycloamide derivative used therein |
GB9721780D0 (en) * | 1997-10-14 | 1997-12-10 | Glaxo Group Ltd | Process for the synthesis of chloropurine intermediates |
CZ298144B6 (cs) * | 1997-11-27 | 2007-07-04 | Lonza Ag | Zpusob výroby (1S,4R)- nebo (1R,4S)-4-(2-amino-6-chlor-9-H-purin-9-yl)-2-cyklopenten-1-methanolu |
GB9802472D0 (en) | 1998-02-06 | 1998-04-01 | Glaxo Group Ltd | Pharmaceutical compositions |
KR100606625B1 (ko) | 1998-10-30 | 2006-07-28 | 론자 아게 | 4-[(2',5'-디아미노-6'-할로피리미딘-4'-일)아미노]-시클로펜트-2-에닐메탄올의 제조 방법 |
US7115584B2 (en) * | 1999-01-22 | 2006-10-03 | Emory University | HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine |
US7635690B2 (en) * | 1999-01-22 | 2009-12-22 | Emory University | HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine |
GB9903091D0 (en) * | 1999-02-12 | 1999-03-31 | Glaxo Group Ltd | Therapeutic nucleoside compound |
US6514979B1 (en) * | 1999-03-03 | 2003-02-04 | University Of Maryland Biotechnology Institute | Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor |
US7205404B1 (en) * | 1999-03-05 | 2007-04-17 | Metabasis Therapeutics, Inc. | Phosphorus-containing prodrugs |
BR0011767A (pt) | 1999-06-28 | 2002-04-23 | Biocryst Pharm Inc | ésteres de (-) -(1s,4r) n protegido 4-amino-2-ciclopenteno-1-carboxilato e respectivos processos de preparação |
US7026469B2 (en) * | 2000-10-19 | 2006-04-11 | Wake Forest University School Of Medicine | Compositions and methods of double-targeting virus infections and cancer cells |
MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
EP1736478B1 (en) | 2000-05-26 | 2015-07-22 | IDENIX Pharmaceuticals, Inc. | Methods and compositions for treating flaviviruses and pestiviruses |
US7309696B2 (en) | 2000-10-19 | 2007-12-18 | Wake Forest University | Compositions and methods for targeting cancer cells |
JP2004520175A (ja) * | 2001-05-29 | 2004-07-08 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 金属−セラミック接合 |
JP2003007697A (ja) * | 2001-06-21 | 2003-01-10 | Hitachi Kokusai Electric Inc | 半導体装置の製造方法、基板処理方法および基板処理装置 |
MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
IL160080A0 (en) * | 2001-08-31 | 2004-06-20 | Thomson Licensing Sa | Sequence counter for an audio visual stream |
KR20040088519A (ko) | 2002-02-22 | 2004-10-16 | 뉴 리버 파마슈티칼스, 인크. | 활성 제제 전달 시스템 및 활성 제제의 보호 및 투여 방법 |
JP5420135B2 (ja) * | 2002-03-15 | 2014-02-19 | ウエイン・ステイト・ユニバーシテイ | 抗ウイルス薬としての新規2−アミノ−9−[(2−ヒドロキシメチル)シクロプロピリデンメチル]プリン |
AR039540A1 (es) | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
KR20050035194A (ko) * | 2002-06-28 | 2005-04-15 | 이데닉스 (케이만) 리미티드 | 플라비비리다에 감염 치료용 2'-c-메틸-3'-o-l-발린에스테르 리보푸라노실 사이티딘 |
NZ537662A (en) * | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
BR0316363A (pt) * | 2002-11-15 | 2005-10-04 | Idenix Cayman Ltd | Nucleosìdeos 2'-ramificado e mutação de flaviviridae |
EP2319853B1 (en) * | 2002-12-12 | 2014-03-12 | IDENIX Pharmaceuticals, Inc. | Process for the production of 2'-branched nucleosides |
US20050010916A1 (en) * | 2003-05-24 | 2005-01-13 | Hagen David A. | System for providing software application updates to multiple clients on a network |
WO2005026141A2 (en) * | 2003-09-17 | 2005-03-24 | Warner-Lambert Company Llc | Process for preparation of substituted butenolides via palladium-free etherification and amination of masked mucohalic acids |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
WO2005051318A2 (en) * | 2003-11-24 | 2005-06-09 | Viropharma Incorporated | Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
US20050187191A1 (en) * | 2004-02-20 | 2005-08-25 | Kucera Louis S. | Methods and compositions for the treatment of respiratory syncytial virus |
DK2258376T3 (en) | 2004-07-27 | 2019-04-15 | Gilead Sciences Inc | Phosphonate analogues of HIV inhibitor compounds |
JP4516863B2 (ja) * | 2005-03-11 | 2010-08-04 | 株式会社ケンウッド | 音声合成装置、音声合成方法及びプログラム |
AU2006276246B2 (en) | 2005-07-25 | 2012-09-27 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis C virus replication |
CN101415705B (zh) | 2005-10-11 | 2011-10-26 | 因特蒙公司 | 抑制丙型肝炎病毒复制的化合物和方法 |
EP1976382B1 (en) * | 2005-12-23 | 2013-04-24 | IDENIX Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
CN100465174C (zh) * | 2006-06-13 | 2009-03-04 | 中国科学院上海有机化学研究所 | 制备光学纯阿巴卡韦的方法 |
KR20090024834A (ko) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규 억제제 |
BRPI0811020A2 (pt) * | 2007-05-03 | 2015-07-21 | Intermune Inc | Composto, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática, de intensificação da função hepática em indivíduo com infecção do vírus da hepatite c e métodos de síntese de compostos, de administração de inibidor da infecção do vírus da hepatite c (hcv) e de distribuição de forma de dosagem oral. |
WO2008141227A1 (en) | 2007-05-10 | 2008-11-20 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
CN101711237B (zh) | 2007-06-12 | 2013-08-07 | 康塞特制药公司 | 氮杂肽衍生物 |
DK2514750T5 (en) | 2007-06-18 | 2014-02-17 | Sunshine Lake Pharma Co Ltd | BROMPHENYL-SUBSTITUTED THIAZOLYLDIHYDROPYRIMIDINES |
EP2085397A1 (en) * | 2008-01-21 | 2009-08-05 | Esteve Quimica, S.A. | Crystalline form of abacavir |
EP2282762A2 (en) | 2008-04-15 | 2011-02-16 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
WO2010077613A1 (en) | 2008-12-09 | 2010-07-08 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
AU2009329917B2 (en) | 2008-12-23 | 2016-03-31 | Gilead Pharmasset Llc | Nucleoside analogs |
MX2011006891A (es) | 2008-12-23 | 2011-10-06 | Pharmasset Inc | Fosforamidatos de nucleosidos. |
CL2009002206A1 (es) | 2008-12-23 | 2011-08-26 | Gilead Pharmasset Llc | Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales. |
AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
EP2305680A3 (en) * | 2009-09-30 | 2011-05-18 | Aurobindo Pharma Limited | Novel salts of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol |
CN102791129B (zh) | 2010-01-27 | 2015-09-30 | Viiv保健公司 | 抗病毒治疗 |
US20110223131A1 (en) | 2010-02-24 | 2011-09-15 | Gilead Sciences, Inc. | Antiviral compounds |
PE20130151A1 (es) | 2010-03-31 | 2013-02-21 | Gilead Pharmasset Llc | Sintesis estereoselectiva de activos que contienen fosforo |
JO3387B1 (ar) | 2011-12-16 | 2019-03-13 | Glaxosmithkline Llc | مشتقات بيتولين |
DK2800750T3 (en) * | 2012-01-03 | 2017-02-27 | Cellceutix Corp | Carbocyclic nucleosides and their pharmaceutical use and compositions |
AU2013340559B2 (en) | 2012-10-29 | 2018-03-15 | Cipla Limited | Antiviral phosphonate analogues and process for preparation thereof |
SG10201704467SA (en) | 2012-12-14 | 2017-06-29 | Glaxosmithkline Llc | Pharmaceutical compositions |
WO2015049623A1 (en) | 2013-10-03 | 2015-04-09 | Lupin Limited | Crystalline abacavir hydrochloride monohydrate and process for its preparation |
CN106061984A (zh) | 2014-02-13 | 2016-10-26 | 配体药物公司 | 前药化合物及其用途 |
KR102252617B1 (ko) * | 2014-02-24 | 2021-05-17 | 삼성전자 주식회사 | 데이터 전송 방법 및 이를 구현하는 장치 |
WO2016001907A1 (en) | 2014-07-02 | 2016-01-07 | Prendergast Patrick T | Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents. |
WO2016003812A1 (en) | 2014-07-02 | 2016-01-07 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and uses therof |
PT3166607T (pt) | 2014-07-11 | 2022-12-07 | Gilead Sciences Inc | Moduladores de receptores de tipo toll para o tratamento do vih |
CA2961528A1 (en) | 2014-09-26 | 2016-03-31 | Glaxosmithkline Intellectual Property (No.2) Limited | Long acting pharmaceutical compositions |
EP3203995A4 (en) * | 2014-10-09 | 2019-05-15 | Board of Regents of the University of Nebraska | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS |
WO2016067182A2 (en) * | 2014-10-27 | 2016-05-06 | Granules India Limited | Process for the preparation of amino alcohol derivatives or salts thereof |
CN104974051A (zh) * | 2015-06-30 | 2015-10-14 | 苏州开元民生科技股份有限公司 | (1S,4R)-cis-4-氨基-2-环戊烯-1-甲醇盐酸盐的合成方法 |
GB201513601D0 (en) * | 2015-07-31 | 2015-09-16 | Univ Liverpool | Antiviral compounds |
MA42818A (fr) | 2015-09-15 | 2018-07-25 | Gilead Sciences Inc | Modulateurs de récepteurs de type toll pour le traitement du vih |
JP2018537502A (ja) * | 2015-12-16 | 2018-12-20 | サウザーン リサーチ インスチチュート | ピロロピリミジン化合物、キナーゼlrrk2阻害剤としての使用、及びその調製方法 |
WO2017141104A2 (en) * | 2016-02-18 | 2017-08-24 | Immune Therapeutics, Inc. | Method for inducing a sustained immune response |
WO2017201179A1 (en) * | 2016-05-18 | 2017-11-23 | Innovation Pharmaceuticals Inc. | Methods of preparing carbocyclic nucleosides |
RU2020126177A (ru) | 2018-01-09 | 2022-02-10 | Лиганд Фармасьютикалз, Инк. | Ацетальные соединения и их терапевтическое применение |
EP3737359A4 (en) | 2018-01-12 | 2021-11-03 | Board of Regents of the University of Nebraska | ANTIVIRAL PRODRUGS AND THEIR FORMULATIONS |
US11458136B2 (en) | 2018-04-09 | 2022-10-04 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and formulations thereof |
WO2020022486A1 (ja) * | 2018-07-27 | 2020-01-30 | 富士フイルム株式会社 | シクロペンテニルプリン誘導体またはその塩 |
CN111393444B (zh) * | 2019-01-02 | 2022-10-28 | 上海迪赛诺化学制药有限公司 | 一种阿巴卡韦羟基醋酸酯的制备方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3148363A1 (de) * | 1980-12-12 | 1982-09-16 | Toyo Jozo K.K., Shizuoka | Neplanocin a-derivate |
US4543255A (en) * | 1984-05-10 | 1985-09-24 | Southern Research Institute | Carbocyclic analogs of purine 2'-deoxyribofuranosides |
US4605659A (en) * | 1985-04-30 | 1986-08-12 | Syntex (U.S.A.) Inc. | Purinyl or pyrimidinyl substituted hydroxycyclopentane compounds useful as antivirals |
KR870002141A (ko) * | 1985-08-16 | 1987-03-30 | 배리 안토니 뉴샘 | 구아닌 유도체의 제조 방법 및 이 유도체를 함유하는 제약 조성물 |
JPS62177234A (ja) * | 1986-01-30 | 1987-08-04 | Mitsubishi Heavy Ind Ltd | 遠心紡糸によるカ−ボン繊維の製造装置 |
IN164556B (cs) * | 1986-03-06 | 1989-04-08 | Takeda Chemical Industries Ltd | |
US4954504A (en) * | 1986-11-14 | 1990-09-04 | Ciba-Geigy Corporation | N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity |
US4859677A (en) * | 1987-04-17 | 1989-08-22 | University Of Kansas | Nucleoside analogues having antiviral activity |
JPS6422853A (en) * | 1987-07-17 | 1989-01-25 | Asahi Glass Co Ltd | Nucleoside analog |
US4916224A (en) * | 1988-01-20 | 1990-04-10 | Regents Of The University Of Minnesota | Dideoxycarbocyclic nucleosides |
SE505213C2 (sv) * | 1988-01-20 | 1997-07-14 | Univ Minnesota | Dideoxikarbocykliska nukleosidanaloger, farmaceutiska beredningar därav samt mellanprodukter |
US4931559A (en) * | 1988-01-20 | 1990-06-05 | Regents Of The University Of Minnesota | Optically-active isomers of dideoxycarbocyclic nucleosides |
US4950758A (en) * | 1988-01-20 | 1990-08-21 | Regents Of The University Of Minnesota | Optically-active isomers of dideoxycarbocyclic nucleosides |
US4787554A (en) * | 1988-02-01 | 1988-11-29 | Honeywell Inc. | Firing rate control system for a fuel burner |
GB8808458D0 (en) * | 1988-04-11 | 1988-05-11 | Metal Box Plc | Food containers |
US5015739A (en) * | 1988-04-22 | 1991-05-14 | Schering Corporation | Processes for preparation of cyclopentyl purine derivatives |
NZ229453A (en) * | 1988-06-10 | 1991-08-27 | Univ Minnesota & Southern Rese | A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents |
ZA894534B (en) * | 1988-06-20 | 1990-03-28 | Merrell Dow Pharma | Novel neplanocin derivatives |
GB8815265D0 (en) * | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
US4939252A (en) * | 1989-04-20 | 1990-07-03 | Hoffmann-La Roche Inc. | Novel intermediates for the preparation of Carbovir |
ATE118208T1 (de) * | 1989-10-16 | 1995-02-15 | Chiroscience Ltd | Chirale azabicycloheptanone und verfahren zu ihrer herstellung. |
US5126452A (en) * | 1990-04-06 | 1992-06-30 | Glaxo Inc. | Synthesis of purine substituted cyclopentene derivatives |
-
1988
- 1988-06-27 GB GB888815265A patent/GB8815265D0/en active Pending
-
1989
- 1989-06-23 CA CA000603768A patent/CA1340589C/en not_active Expired - Lifetime
- 1989-06-26 AT AT89306467T patent/ATE120194T1/de not_active IP Right Cessation
- 1989-06-26 IL IL9075289A patent/IL90752A/en not_active IP Right Cessation
- 1989-06-26 DE DE68921798T patent/DE68921798T2/de not_active Expired - Lifetime
- 1989-06-26 DK DK198903156A patent/DK174668B1/da not_active IP Right Cessation
- 1989-06-26 PT PT90973A patent/PT90973B/pt not_active IP Right Cessation
- 1989-06-26 JP JP1163629A patent/JP2875814B2/ja not_active Expired - Lifetime
- 1989-06-26 ZA ZA894837A patent/ZA894837B/xx unknown
- 1989-06-26 AP APAP/P/1989/000129A patent/AP101A/en active
- 1989-06-26 AU AU37025/89A patent/AU636108B2/en not_active Expired
- 1989-06-26 FI FI893113A patent/FI893113A/fi not_active Application Discontinuation
- 1989-06-26 IE IE206189A patent/IE68038B1/en not_active IP Right Cessation
- 1989-06-26 HU HU893215A patent/HU206353B/hu unknown
- 1989-06-26 NZ NZ229716A patent/NZ229716A/en unknown
- 1989-06-26 MY MYPI89000860A patent/MY104043A/en unknown
- 1989-06-26 ES ES89306467T patent/ES2069582T3/es not_active Expired - Lifetime
- 1989-06-26 EP EP89306467A patent/EP0349242B1/en not_active Expired - Lifetime
- 1989-09-26 FI FI894545A patent/FI102680B/fi active IP Right Grant
- 1989-09-26 KR KR1019890013812A patent/KR0140532B1/ko not_active IP Right Cessation
- 1989-12-22 US US07/455,201 patent/US5034394A/en not_active Expired - Lifetime
- 1989-12-22 US US07/455,538 patent/US5049671A/en not_active Expired - Lifetime
-
1990
- 1990-12-19 US US07/630,129 patent/US5087697A/en not_active Expired - Lifetime
- 1990-12-21 JP JP2419050A patent/JP2963775B2/ja not_active Expired - Lifetime
- 1990-12-21 CZ CS922470A patent/CZ283786B6/cs not_active IP Right Cessation
- 1990-12-21 UA UA5011830A patent/UA29382C2/uk unknown
-
1991
- 1991-05-08 US US07/697,260 patent/US5089500A/en not_active Expired - Lifetime
- 1991-09-27 US US07/767,134 patent/US5206435A/en not_active Expired - Lifetime
-
1995
- 1995-04-28 GR GR950401089T patent/GR3015966T3/el unknown
- 1995-06-20 HU HU95P/P00288P patent/HU211537A9/hu unknown
-
1996
- 1996-07-16 LV LV960240A patent/LV5781B4/xx unknown
-
1997
- 1997-06-19 HK HK85897A patent/HK85897A/xx not_active IP Right Cessation
-
1998
- 1998-02-20 CY CY201898A patent/CY2018A/xx unknown
- 1998-09-14 JP JP10259574A patent/JPH11139976A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CZ247092A3 (cs) | Cyklopentenové deriváty | |
SK280000B6 (sk) | Enantiomérne 4-amino-2-cyklopentén-1-metanoly | |
KR19990021899A (ko) | (-) 6-클로로-4-사이클로프로필-에티닐-4-트리플루오로메틸-1,4-디하이드로-2h-3,1-벤즈옥사진-2-온의 비대칭성 합성 방법 | |
JP3107829B2 (ja) | シクロプロピルアセチレンの改良型合成法 | |
HU207081B (en) | Process for producing compounds with purine skeleton and pharmaceutical compositions comprising same | |
JP2004506606A (ja) | 抗ウイルスピリミジンヌクレオシド類 | |
IE913751A1 (en) | Synergism of hiv reverse transcriptase inhibitors | |
HU182544B (en) | Process for preparing complexes of hydroxy-alkyl-purines with amino-alkanol and p-acetamido-benzoic acid | |
JPH0324080A (ja) | N‐ヘテロアリール‐プリン‐6‐アミンおよびその製法 | |
EP0361831B1 (en) | Antiviral nucleoside combination | |
RU2120939C1 (ru) | 6-[x-(2-гидроксиэтил)аминоалкил]-5,11-диоксо-5,6-дигидро-11h-инде- но/1,2-с/изохинолины или их соли с неорганическими и органическими кислотами, способы их получения и фармацевтическая композиция на их основе | |
EP0290558B1 (en) | Antifolate agents | |
JP3164361B2 (ja) | 治療用ヌクレオシド | |
CN111484541A (zh) | 双核苷酸前体药物及其制备方法 | |
JPH06506916A (ja) | アミド誘導体およびそれらの治療への使用 | |
KR890000621B1 (ko) | 불소화된 디아미노알켄 유도체의 제조방법 | |
JPH03503050A (ja) | 抗レトロウイルス剤としてのピリミジンおよびプリン1,2‐ブタジエン‐4‐オール | |
US20040192724A1 (en) | Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents | |
HU220668B1 (hu) | Enantiomer purinszármazékok és előállításuk | |
JPS60142986A (ja) | プリン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
IF00 | In force as of 2000-06-30 in czech republic | ||
MK4A | Patent expired |
Effective date: 20101221 |